目的：分析成人急性淋巴细胞白血病（ALL）患者的SLC19A1启动子区域甲基化水平，并探讨甲氨蝶呤（MTX）药物代谢与SLC19A1甲基化之间的关系。方法：回顾性分析52例接受高剂量MTX化疗的成人ALL患者的SLC19A1启动子区域甲基化水平，并结合临床指标和血浆MTX浓度。结果：17个CpG单位的甲基化水平与ALL患者的性别、年龄、免疫表型和费城染色体状态等临床参数呈不同程度的相关。MTX药物排泄延迟的患者在SLC19A1启动子区域中甲基化水平较高。结论：甲基化可能影响MTX血浆水平和不良反应，可预测高剂量MTX治疗后有不良反应风险的患者。

Aims: To analyze the methylation level in the promoter region of SLC19A1 in adult acute lymphoblastic leukemia (ALL) patients, and explore the relationship between methotrexate (MTX) drug metabolism and SLC19A1 methylation. Methods: The methylation levels of the SLC19A1 promoter region in 52 adult ALL patients who received high-dose MTX chemotherapy were retrospectively analyzed in combination with clinical indicators and plasma MTX concentration. Results: Methylation levels of 17 CpG units were differently correlated with clinical parameters of ALL patients including gender, age, immunophenotype and Philadelphia chromosome status. Patients with delayed MTX drug excretion had higher methylation levels in the SLC19A1 promoter region. Conclusion: The methylation may affect the MTX plasma level and adverse reactions, which may predict patients at risk of adverse reactions after high-dose MTX therapy.